IL6 and neoplasm: In the Tumor–Myeloid interaction, enrichment was observed in immune-related pathways such as ‘IL-6/JAK/STAT3 Signaling’, ‘Cytokine–cytokine receptor interaction’, ‘Inflammatory Response’, and ‘Chemokine binding’.